TRPV1 Is a Potential Tumor Suppressor for Its Negative Association with Tumor Proliferation and Positive Association with Antitumor Immune Responses in Pan-Cancer

Figure 2

Correlations of TRPV1 expression with clinical characteristics and cancer subtypes. TRPV1 expression levels correlate positively with survival prognosis (a) and are lower in late-stage than in early-stage tumors in pan-cancer (b). TRPV1 expression levels are significantly higher in papillary than in nonpapillary subtypes of BLCA, and the papillary subtype has a better OS than the nonpapillary subtype (c). In BRCA, TRPV1 expression is significantly lower in basal-like than in luminal A&B and in HER2-enriched than in luminal A&B (d). In LGG, TRPV1 expression levels are significantly higher in IDH-mutated than in IDH-wild-type tumors, and the IDH-mutated subtype has a better OS than the IDH-wild-type subtype (e). OS: overall survival; DSS: disease-specific survival; PFI: progression-free interval. The log-rank test values, the Chi-squared test values, and Student’s -test values are shown.

(a)

(b)

(c)

(d)

(e)